

Hyperphosphatemia - Pipeline Insight, 2021

<https://marketpublishers.com/r/HC18873778BEN.html>

Date: May 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: HC18873778BEN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Hyperphosphatemia - Pipeline Insight, 2021," report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Hyperphosphatemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Hyperphosphatemia Understanding

Hyperphosphatemia: Overview

Hyperphosphatemia—that is, abnormally high serum phosphate levels—can result from increased phosphate intake, decreased phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space. However, even severe hyperphosphatemia is for the most part clinically asymptomatic. Morbidity In patients with this condition is more commonly associated with an underlying disease than with increased phosphate values.

'Hyperphosphatemia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hyperphosphatemia pipeline landscape is provided which

includes the disease overview and Hyperphosphatemia treatment guidelines. The assessment part of the report embraces, in depth Hyperphosphatemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hyperphosphatemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Hyperphosphatemia R&D. The therapies under development are focused on novel approaches to treat/improve Hyperphosphatemia.

Hyperphosphatemia Emerging Drugs Chapters

This segment of the Hyperphosphatemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hyperphosphatemia Emerging Drugs

FC818 (ferric citrate): PUMC Pharmaceutical

FC818 is a novel non-calcium-based phosphate binder. One Phase I and two pivotal Phase II clinical trials showed FC818 to be an effective and safe treatment for lowering and/or maintaining serum phosphorus levels

Contents

Introduction

Executive Summary

Hyperphosphatemia: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Hyperphosphatemia – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Hyperphosphatemia companies' collaborations, Licensing, Acquisition -Deal Value

Trends

Hyperphosphatemia Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

FC 818: PUMC Pharmaceutical

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Mid Stage Products (Phase II)

Comparative Analysis

VS 505: Shanghai Alebund Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Inactive Products

Comparative Analysis

Hyperphosphatemia Key Companies

Hyperphosphatemia Key Products

Hyperphosphatemia- Unmet Needs

Hyperphosphatemia- Market Drivers and Barriers

Hyperphosphatemia- Future Perspectives and Conclusion

Hyperphosphatemia Analyst Views

Hyperphosphatemia Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Hyperphosphatemia

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Hyperphosphatemia
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Hyperphosphatemia - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/HC18873778BEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HC18873778BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970